Plain-English translation of NCT07430306 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called , given as a weekly injection under the skin, for people with systemic lupus erythematosus (lupus) who have not yet tried biologic therapies or strong immunosuppressant drugs. Lupus is an autoimmune disease where the body's immune system attacks its own tissues, causing pain, fatigue, and organ damage. Researchers want to see if this medication can reduce lupus symptoms and help patients lower or stop their steroid medications.
Most people with lupus currently take antimalarial drugs and steroids, but many still have active disease or struggle with steroid side effects. This medication targets a specific part of the immune system involved in lupus, and researchers hope it can work better for people who haven't yet tried biologic treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic every week for 52 weeks to receive an injection of the medication under your skin using a pen device (similar to an insulin pen). The study includes an initial screening period of up to 5 weeks, followed by the 52-week treatment phase. During the study, doctors will monitor your lupus activity through blood tests and clinical assessments, and they will try to gradually reduce your steroid dose if your disease improves. If you stop the medication after week 52, you would have additional follow-up visits for 12 weeks afterward to monitor your safety.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States